Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemiaYishai Ofran, Avraham Frisch, Ofrat Beyar‐Katz et al.|Leukemia|2019Cited by 69